CA2674458A1 - Fusion protein - Google Patents

Fusion protein Download PDF

Info

Publication number
CA2674458A1
CA2674458A1 CA002674458A CA2674458A CA2674458A1 CA 2674458 A1 CA2674458 A1 CA 2674458A1 CA 002674458 A CA002674458 A CA 002674458A CA 2674458 A CA2674458 A CA 2674458A CA 2674458 A1 CA2674458 A1 CA 2674458A1
Authority
CA
Canada
Prior art keywords
seq
eso
lage
fusion protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002674458A
Other languages
English (en)
French (fr)
Inventor
Normand Blais
Martine Boyer
Vincent Brichard
Jamila Louahed
Denis Martin
Remi M. Palmantier
Clement Rioux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700759A external-priority patent/GB0700759D0/en
Priority claimed from GB0709707A external-priority patent/GB0709707D0/en
Application filed by Individual filed Critical Individual
Publication of CA2674458A1 publication Critical patent/CA2674458A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002674458A 2007-01-15 2008-01-11 Fusion protein Abandoned CA2674458A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0700759A GB0700759D0 (en) 2007-01-15 2007-01-15 Novel fusion protein
GB0700759.4 2007-01-15
US91484807P 2007-04-30 2007-04-30
US91492507P 2007-04-30 2007-04-30
US60/914,848 2007-04-30
US60/914,925 2007-04-30
GB0709707.4 2007-05-21
GB0709707A GB0709707D0 (en) 2007-05-21 2007-05-21 Novel fusion protein
PCT/US2008/050879 WO2008089074A2 (en) 2007-01-15 2008-01-11 Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1

Publications (1)

Publication Number Publication Date
CA2674458A1 true CA2674458A1 (en) 2008-07-24

Family

ID=41111108

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002674458A Abandoned CA2674458A1 (en) 2007-01-15 2008-01-11 Fusion protein

Country Status (15)

Country Link
EP (1) EP2118128B1 (enExample)
JP (1) JP2010532656A (enExample)
KR (1) KR20090122426A (enExample)
BR (1) BRPI0806501A2 (enExample)
CA (1) CA2674458A1 (enExample)
DK (1) DK2118128T3 (enExample)
EA (1) EA016818B1 (enExample)
ES (1) ES2398492T3 (enExample)
HR (1) HRP20130022T1 (enExample)
MX (1) MX2009007572A (enExample)
PE (1) PE20081687A1 (enExample)
PL (1) PL2118128T3 (enExample)
SI (1) SI2118128T1 (enExample)
TW (1) TW200902049A (enExample)
WO (1) WO2008089074A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
CN102575284A (zh) 2009-03-17 2012-07-11 MDx健康公司 改进的基因表达检测
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
CN103957930A (zh) * 2011-08-31 2014-07-30 国立大学法人三重大学 癌症治疗用疫苗制剂
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
US20160367651A1 (en) 2013-10-01 2016-12-22 Mie University T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation
US10253062B2 (en) 2014-12-23 2019-04-09 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
SG11201807036QA (en) 2016-02-26 2018-09-27 Auckland Uniservices Ltd Amino acid and peptide conjugates and conjugation process
EP3883600B1 (en) * 2018-11-23 2025-03-12 Strike Pharma AB Bi-specific conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06205672A (ja) * 1992-03-19 1994-07-26 Nippon Zeon Co Ltd 日本脳炎ウイルス及びｂ型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
ES2362715T3 (es) * 2000-03-30 2011-07-12 Dendreon Corporation Composiciones y métodos para inmunoterapia a base de células dendríticas.
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
MXPA06007144A (es) * 2003-12-24 2007-01-31 Cerus Corp Moleculas de acido nucleico recombinante que codifican proteinas de fusion que comprenden polipeptidos de senal secretoria bacterial y de antigenos, casetes de expresion y bacterias, y metodos para usar las mismas.
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
EP1812580B1 (en) * 2004-11-16 2014-12-17 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
JP2009538286A (ja) * 2006-05-26 2009-11-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 癌に対するワクチン接種
NZ578285A (en) * 2007-01-15 2011-12-22 Glaxosmithkline Biolog Sa Fusion protein comprising a prame linked to a immunological fusion partner protein and additional amino acids at the n terminal end of the fusion partner sequence

Also Published As

Publication number Publication date
EA016818B1 (ru) 2012-07-30
MX2009007572A (es) 2009-10-13
EA200900738A1 (ru) 2010-02-26
KR20090122426A (ko) 2009-11-30
TW200902049A (en) 2009-01-16
EP2118128B1 (en) 2012-11-07
BRPI0806501A2 (pt) 2014-04-22
HRP20130022T1 (hr) 2013-02-28
ES2398492T3 (es) 2013-03-19
WO2008089074A9 (en) 2012-07-12
PL2118128T3 (pl) 2013-03-29
PE20081687A1 (es) 2008-12-25
DK2118128T3 (da) 2013-02-18
WO2008089074A2 (en) 2008-07-24
JP2010532656A (ja) 2010-10-14
EP2118128A2 (en) 2009-11-18
WO2008089074A3 (en) 2008-12-31
SI2118128T1 (sl) 2013-02-28

Similar Documents

Publication Publication Date Title
EP2118128B1 (en) Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
AU2008207025B2 (en) Vaccine
EP1659179B1 (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
US8916514B2 (en) CASB7439 constructs
US8309096B2 (en) Fusion protein
AU2008206463B2 (en) Fusion proteins comprising the tumor rejection antigens NY-ESO-1 and LAGE-1
JP7513303B2 (ja) 腫瘍免疫増強剤、その調製方法および適用
ES2367998T3 (es) Derivados antígenos asociados a tumores de la familia mage, y secuencias de ácidos nucleicos que los codifican, usados para la preparación de proteínas de fusión y de composiciones para vacunación.
CN101583623A (zh) 包含肿瘤排斥抗原ny-eso-1和lage-1的融合蛋白
MXPA00007677A (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
HK1138853B (en) Vaccine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130110

FZDE Discontinued

Effective date: 20150928